Aveo Oncology: The FDA Approved FOTIVDA for Adults with Relapsed or Refractory Advanced RCC
March 11, 2021
0
Aveo Oncology Received FDA Approval for FOTIVDA for Advanced RCC Aveo Oncology (AVEO) drug FOTIVDA is an oral, next-generation vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI). It is a potent, selective inhibitor of VEGFRs 1, 2, and 3 with a long half-life designed to improve efficacy and tolerability. AVEO plans to make FOTIVDA available to patients in the U.S. by March 31, 2021. …